


GUERNSEY STATUTORY INSTRUMENT
2021 No. 16



**The Health Service (Benefit) (Limited List) (Pharmaceutical
Benefit) (Amendment) Regulations, 2021**

<i>Made</i>	<i>9th February, 2021</i>
<i>Coming into operation</i>	<i>10th February, 2021</i>
<i>Laid before the States</i>	<i>, 2021</i>

THE COMMITTEE FOR HEALTH & SOCIAL CARE, in exercise of the powers conferred on it by sections 10 and 35 of the Health Service (Benefit) (Guernsey) Law, 1990^a and section 1 of the Health Service (Benefit) (Limited Lists) Ordinance, 2004^b, and all other powers enabling it in that behalf, hereby makes the following Regulations:-

Amendment to the 2004 Regulations.

1. In the Schedule to the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) Regulations, 2004^c ("the Schedule") -

^a Ordres en Conseil Vol. XXXII, p. 192; amended by Order in Council No. IX of 2003; No. II of 2011; No. IV of 2018; Recueil d'Ordonnances Tome XXVI, pp. 177 and 483; Ordinance No. XXII of 2002; No XXVII of 2002; No. XXI of 2003; No. XXXIII of 2003; No. XLII of 2006; No. XLIII of 2007; No. XXII of 2015; No. IX of 2016; No. XLIV of 2016; and No. XVI of 2020. Applied with modifications by Recueil d'Ordonnances Tome XXV, p. 204; Tome XXVI, p. 484; Tome XXVII, p. 200; and Tome XXVIII, p. 1.

^b Ordinance No. XIII of 2004; amended by No. XXXIV of 2013 and No. XXV of 2017.

^c G.S.I. No. 9 of 2004 as amended by G.S.I. No. 42 of 2004; No's 18, 25 and 38 of 2005; No's 12, 18, 26, 36 and 46 of 2006; No's 3, 5, 6, 16, 17 and 32 of 2007; No's 11, 23, 29, 31, 47, 50 and 76 of 2008; No's 16, 35, 43, 47 and 56 of 2009; No's 5, 32, 48, 88, 91 and 99 of 2010; No's 5, 13, 19, 37, 38 and 52 of 2011; No's 5, 25, 33 and 52 of 2012; No's 5, 27, 35, 42, 68, 78 and 87 of 2013; No's 8, 11, 16, 25, 57, 69 and 99 of 2014; No's 9, 33 and 106 of 2015; No's 10, 17, 25, 31 and


- (a) insert the rows set out in Schedule 1 to these Regulations in the appropriate places and under the appropriate headings, as set out in the Schedule, and
- (b) substitute the entries relating to Dabigatran etexilate and Empagliflozin in the rows of the Schedule referred to in columns 1 and 2 of Schedule 2 to these Regulations for the appropriate entry set out in column 3 of Schedule 2 to these Regulations.

Citation, commencement and extent.

2. (1) These Regulations may be cited as the Health Service (Benefit) (Limited List) (Pharmaceutical Benefit) (Amendment) Regulations, 2021, and shall come into force on the 10th day of February, 2021.

(2) These Regulations shall have effect in the Islands of Guernsey, Alderney, Herm and Jethou.

Dated this 9th day of February, 2021.



A. H. BROUARD

President of the States Committee for Health & Social Care

For and on behalf of the Committee

SCHEDULE 1

ROWS TO BE INSERTED IN THE SCHEDULE TO THE 2004 REGULATIONS

British National Formulary (BNF) Section	Heading	Pharmaceutical Benefit
1.2	Antispasmodics and other drugs altering the gut motility	Eluxadoline, film-coated tablets, 75mg and 100mg (in accordance with NICE TA number 471 or any revision(s) thereof only)
1.5	Chronic bowel disorders	Mesalazine MR, gastro-resistant tablets, 400mg and 800mg
1.6	Laxatives	Naldemedine, film-coated tablets, 200mcg (in accordance with NICE TA number 651 or any revision thereof only)
1.6.6	Peripheral Opioid-receptor Antagonists	Naloxegol, film-coated tablets, 12.5mg and 25mg (in accordance with NICE TA number 345 or any revision thereof only)
2.8	Anticoagulants and protamine	Rivaroxaban, film-coated tablets, 2.5mg (in accordance with NICE TA number 607 or any revision thereof only)
2.9	Antiplatelet Drugs	Ticagrelor, film-coated tablets and orodispersible tablets, 90mg (in combination with low-dose aspirin) (in accordance with NICE TA number 236 or any revision thereof only)
2.9	Antiplatelet Drugs	Ticagrelor, film-coated tablets, 60mg (in combination with aspirin) (in accordance with NICE TA number 420 or any revision thereof only)
3.3.3	Phosphodiesterase type-4 inhibitors	Roflumilast, tablets, 250mcg, and film-coated tablets, 500mcg (in accordance with NICE TA number 461 or any revision thereof only)
3.4.2	Allergen Immunotherapy	Pharmalgen Bee Venom (<i>Apis mellifera</i>), freeze-dried powder and solvent for solution for injection, 120mcg, and Pharmalgen Wasp Venom (<i>Vespula spp.</i>), freeze-dried powder and solvent for solution for injection, 120mcg.

		(in accordance with NICE TA number 246 or any revision thereof only)
4.3.4	Other Antidepressants	Vortioxetine, film-coated tablets, 5mg, 10mg, 15mg and 20mg (in accordance with NICE TA number 367 or any revision thereof only)
4.10	Drugs used in substance dependence	Buprenorphine oral lyophilisates sugar-free, 2mg, 8mg (for CDAT prescribing and according to local guidelines only)
5.3	Antiviral	Elbasvir–grazoprevir, film-coated tablets, 50mg/100mg (PEH pharmacy dispensing only and in accordance with NICE TA number 413 or any revision thereof only)
6.1.2	Antidiabetic drugs	Dapagliflozin/Metformin, film-coated tablets, 5mg/850mg and 5mg/1,000mg (second line SGLT2 and in accordance with NICE TA number 288 or any revision thereof only)
6.1.2	Antidiabetic drugs	Dapagliflozin, film-coated tablets, 10mg (second line SGLT2 and in accordance with NICE TA number 390 or any revision thereof only)
6.1.2	Antidiabetic drugs	Dapagliflozin, film-coated tablets, 5mg (second line SGLT2 and in accordance with NICE TA number 597 or any revision thereof only)
6.1.2	Antidiabetic drugs	Canagliflozin hemihydrate, film-coated tablets, 100mg and 300mg (second line SGLT2 and in accordance with NICE TA number 390 or any revision thereof only)
6.1.2	Antidiabetic drugs	Sotagliflozin, tablets, 200mg (second line SGLT 2 and in accordance with NICE TA number 622 or any revision thereof only)
7.4.2	Drugs for urinary frequency, enuresis, and incontinence	Mirabegron, prolonged-release tablets, 25mg and 50mg (in accordance with NICE TA number 290 or any revision thereof only)
8.1	Cytotoxic drugs	Midostaurin, soft capsules, 25mg (PEH Pharmacy dispensing and on-island Consultant Medical Oncologist prescribing and in accordance with NICE TA number 523 or any revision thereof only)

8.2.4	Other Immunomodulating Drugs	Teriflunomide, film-coated tablets, 14 mg (Homecare or PEH pharmacy dispensing and in accordance with NICE TA number 303 or any revision thereof only)
9.2.1	Oral preparations for fluid and electrolyte imbalance	Patiromer, powder for oral suspension, 8.4g, 16.8g and 25.2g (in accordance with NICE TA number 623 or any revision thereof only)
13.5	Preparations for eczema and psoriasis	Ixekizumab, solution for injection in pre-filled syringes and prefilled pens, 80mg (in accordance with NICE TA numbers 442 or 537 or any revision(s) thereof only)
13.5.1	Preparations for eczema (Oral retinoid for eczema)	Alitretinoin, soft capsules, 10mg and 30mg (in accordance with NICE TA number 177 or any revision thereof only)

SCHEDULE 2

ROWS TO BE SUBSTITUTED IN THE SCHEDULE TO THE 2004 REGULATIONS

British National Formulary (BNF) Section	Heading	Pharmaceutical Benefit
2.8	Anticoagulants and protamine	Dabigatran etexilate, hard capsules, 75mg, 110mg and 150mg (in accordance with NICE TA numbers 157 or 249 or 327 or any revision(s) thereof only)
6.1.2	Antidiabetic drugs	Empagliflozin, tablets, 10mg, 25mg (first line SGLT2 and in accordance with NICE TA 336 or any revision thereof)

EXPLANATORY NOTE

(This note is not part of the Regulations)

These Regulations add drugs to the list of drugs that may be prescribed as pharmaceutical benefit and amend the permissible prescribing of two drugs already on that list.

These Regulations come into force on the 10th February, 2021.

